loading page

COVID-19 Infection and Primary Graft Failure in a Pediatric Hematopoietic Stem Cell Transplant Patient
  • +3
  • Minelys Alicea Marrero,
  • Margarita Silio,
  • Katie McQueen Amaker,
  • María Español,
  • Maria Velez,
  • Zachary LeBlanc
Minelys Alicea Marrero
Louisiana State University Health Sciences Center
Author Profile
Margarita Silio
Tulane University School of Medicine
Author Profile
Katie McQueen Amaker
Louisiana State University Health Sciences Center
Author Profile
María Español
Louisiana State University Health Sciences Center
Author Profile
Maria Velez
Louisiana State University Health Sciences Center
Author Profile
Zachary LeBlanc
Louisiana State University Health Sciences Center
Author Profile

Abstract

Currently, data on the effects of the novel Coronavirus disease (COVID-19) on hematopoietic stem cell transplant (HSCT) recipients is limited. In this case, an 8-year-old male with IPEX syndrome underwent allogeneic HSCT and was found COVID-19 positive 23 days post-transplant. He was treated with a 10-day course of remdesivir, three doses of tocilizumab, and two units of COVID-19 convalescent plasma (CCP). Initially, inflammatory markers decreased with treatment. However, he experienced primary graft failure, most likely secondary to COVID-19 infection, developed multiple systemic infections, and subsequently died before a second graft infusion could be administered.